Sign In
Buy BTAI
$1.26
-0.0400 (-3.08%)
At Close: Jun 23, 2026
BioXcel Therapeutics slumps 23% after FDA extended PDUFA date for BXCL501
12:33pm, Wednesday, 01'st Dec 2021 Seeking Alpha
BioXcel Therapeutics Announces Extension of FDA Review Period of its NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders
12:00pm, Wednesday, 01'st Dec 2021 GlobeNewswire Inc.
PDUFA date extended by three months to April 5, 2022
BioXcel Therapeutics Announces Extension of FDA Review Period of its NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders
12:00pm, Wednesday, 01'st Dec 2021 Intrado Digital Media
PDUFA date extended by three months to April 5, 2022
BioXcel Therapeutics (BTAI) Stock: Why The Price Substantially Fell Today
08:54am, Wednesday, 01'st Dec 2021
The stock price of BioXcel Therapeutics, Inc. (Nasdaq: BTAI) fell by over 18% pre-market today. This is why it happened.
Why BioXcel Therapeutics Is Down Sharply This Week
02:56pm, Friday, 19'th Nov 2021 The Motley Fool
A double downgrade from an analyst on Wall Street is causing investors to think twice about the company's first new drug launch.
Why BioXcel Therapeutics Stock Is Crashing Today
05:54pm, Monday, 15'th Nov 2021 The Motley Fool
An analyst downgraded the stock.
BioXcel Therapeutics (NASDAQ:BTAI) Shares Gap Down to $34.53
04:32pm, Monday, 15'th Nov 2021 Dakota Financial News
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) shares gapped down prior to trading on Monday . The stock had previously closed at $34.53, but opened at $29.90. BioXcel Therapeutics shares last traded at $28.60, with a volume of 7,134 shares trading hands. Several equities analysts recently issued reports on the stock. HC Wainwright reiterated a buy rating and []
Why BioXcel Therapeutics Stock Is Crashing Today
12:54pm, Monday, 15'th Nov 2021
An analyst downgraded the stock.
BioXcel Therapeutics to Present at the 2021 Jefferies London Healthcare Conference
07:00am, Thursday, 11'th Nov 2021
NEW HAVEN, Conn., Nov. 11, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transf
BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q3 2021 Results - Earnings Call Transcript
12:25pm, Wednesday, 10'th Nov 2021
BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q3 2021 Results - Earnings Call Transcript
BioXcel Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021
07:00am, Wednesday, 27'th Oct 2021
NEW HAVEN, Conn., Oct. 27, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transf
BioXcel Therapeutics: Ready To Enter The Depression Therapeutic Field
03:48am, Sunday, 24'th Oct 2021
The company intends to expand the indication of BXCL501 to treat anxious depression.
This High-Risk, High-Reward Stock Might Double Your Money
10:00am, Wednesday, 20'th Oct 2021
After a difficult year, shares of this biotech could bounce back big.
Initial findings from Phase 1b/2 trial of BXCL701 in combination with KEYTRUDA met efficacy threshold to support expansion of existing cohort of de novo and treatment-emergent Small-Cell Neuroendocrin
Why BioXcel Therapeutics Stock Is Sinking Today
11:39am, Thursday, 14'th Oct 2021
The company's chief commercial officer resigned.
